Tuesday, July 26, 2011

Flagyl ER


See also: Generic Flagyl


Flagyl ER is a brand name of metronidazole, approved by the FDA in the following formulation(s):


FLAGYL ER (metronidazole - tablet, extended release; oral)



  • Manufacturer: GD SEARLE LLC

    Approval date: November 26, 1997

    Strength(s): 750MG [RLD][AB]

Has a generic version of Flagyl ER been approved?


A generic version of Flagyl ER has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Flagyl ER and have been approved by the FDA:


metronidazole tablet, extended release; oral



  • Manufacturer: ALEMBIC LTD

    Approval date: May 5, 2010

    Strength(s): 750MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Flagyl ER. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Modified-release metronidazole compositions and methods for making and using same
    Patent 6,103,262
    Issued: August 15, 2000
    Inventor(s): Desai; Subhash & Mancini; Alan Mark & Schumann; Steven Charles
    Assignee(s): G. D. Searle & Company
    Pharmaceutical compositions having a modified release profile for once daily dosing of metronidazole, methods for making the pharmaceutical compositions, and methods for treating a microbial infection with once daily dosing of the pharmaceutical compositions of the invention are provided. The compositions given once daily exhibit substantial bioequivalence to immediate release metronidazole given three times per day. The compositions of the invention comprise: (a) a first portion of metronidazole which is about 59 wt % to about 79 wt % metronidazole; (b) about 1.5 wt % to about 3.0 wt % of an aqueous insoluble poly(meth)acrylic acid ester copolymer which is aqueous permeable, aqueous expandable and pH-independent; (c) about 0.1 wt % to about 2.0 wt % detackifier; (d) 0 to about 23 wt % of a first aqueous soluble pharmaceutical diluent; (e) 0 to about 23 wt % of a second aqueous soluble diluent which is suitable for forming a pharmaceutical tablet when compressed with the granules of (a), the second aqueous soluble diluent being the same as or different from the first aqueous soluble diluent; (f) 0 to about 20 wt % of a second portion of metronidazole; (g) 0 to about 0.2 wt % glidant; and (h) 0 to about 2 wt % lubricant; wherein the composition comprises metronidazole containing granules comprising (a), (b), (c) and (d), wherein the sum of the weight percentages of metronidazole provided by (a) and (f) is between about 72 wt % and about 79 wt %, and wherein the sum of the weight percentages of the aqueous soluble diluent provided by (d) and (e) is between about 16 wt % and about 23 wt %.
    Patent expiration dates:

    • August 15, 2017
      ✓ 
      Patent use: METHOD OF TREATING BACTERIAL VAGINOSIS
      ✓ 
      Drug product



See also...

  • Flagyl ER Extended-Release Tablets Consumer Information (Wolters Kluwer)
  • Flagyl ER Consumer Information (Cerner Multum)
  • Flagyl ER Advanced Consumer Information (Micromedex)
  • Metronidazole Consumer Information (Drugs.com)
  • Metronidazole Consumer Information (Wolters Kluwer)
  • Metronidazole Capsules Consumer Information (Wolters Kluwer)
  • Metronidazole Extended-Release Tablets Consumer Information (Wolters Kluwer)
  • Metronidazole Tablets Consumer Information (Wolters Kluwer)
  • Metronidazole Consumer Information (Cerner Multum)
  • Flagyl I.V. RTU Advanced Consumer Information (Micromedex)
  • Flagyl I.V. RTU Intravenous Advanced Consumer Information (Micromedex)
  • Metronidazole Intravenous Advanced Consumer Information (Micromedex)
  • Metronidazole Oral, Intravenous Advanced Consumer Information (Micromedex)
  • Metronidazole AHFS DI Monographs (ASHP)
  • Metronidazole Hydrochloride AHFS DI Monographs (ASHP)

Monday, July 25, 2011

Bimotrim




Bimotrim may be available in the countries listed below.


In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Bimotrim



Sulfadoxine

Sulfadoxine is reported as an ingredient of Bimotrim in the following countries:


  • Luxembourg

  • Sweden

  • United Kingdom

Trimethoprim

Trimethoprim is reported as an ingredient of Bimotrim in the following countries:


  • Luxembourg

  • Sweden

  • United Kingdom

International Drug Name Search

Saturday, July 23, 2011

Avinza


Avinza is a brand name of morphine, approved by the FDA in the following formulation(s):


AVINZA (morphine sulfate - capsule, extended release; oral)



  • Manufacturer: KING PHARMS

    Approval date: March 20, 2002

    Strength(s): 120MG [RLD], 90MG


  • Manufacturer: KING PHARMS

    Approval date: December 18, 2008

    Strength(s): 45MG, 75MG

Has a generic version of Avinza been approved?


No. There is currently no therapeutically equivalent version of Avinza available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Avinza. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Oral morphine multiparticulate formulation
    Patent 6,066,339
    Issued: May 23, 2000
    Inventor(s): Stark; Paul & Cunningham; Sean & Moodley; Jagathesan
    Assignee(s): Elan Corporation, plc
    An oral morphine multiparticulate formulation for once-daily administration to a patient, comprising sustained release particles each having a core containing water soluble morphine and an osmotic agent, the core being coated with a rate-controlling polymer coat comprised of ammonio methacrylate copolymers in an amount sufficient to achieve therapeutically effective plasma levels of morphine over at least 24 hours in the patient.
    Patent expiration dates:

    • November 25, 2017


    • November 25, 2017
      ✓ 
      Drug product



See also...

  • Avinza Consumer Information (Drugs.com)
  • Avinza Extended-Release Capsules Consumer Information (Wolters Kluwer)
  • Avinza Consumer Information (Cerner Multum)
  • Avinza Advanced Consumer Information (Micromedex)
  • Morphine Consumer Information (Drugs.com)
  • Morphine Concentrate Consumer Information (Wolters Kluwer)
  • Morphine Extended-Release Capsules Consumer Information (Wolters Kluwer)
  • Morphine Immediate-Release Consumer Information (Wolters Kluwer)
  • Morphine Immediate-Release Tablets Consumer Information (Wolters Kluwer)
  • Morphine Soluble Tablets Consumer Information (Wolters Kluwer)
  • Morphine Solution Consumer Information (Wolters Kluwer)
  • Morphine Suppositories Consumer Information (Wolters Kluwer)
  • Morphine Sustained-Release Tablets Consumer Information (Wolters Kluwer)
  • Morphine IR Consumer Information (Cerner Multum)
  • Morphine Consumer Information (Cerner Multum)
  • DepoDur Advanced Consumer Information (Micromedex)
  • Morphine Advanced Consumer Information (Micromedex)
  • Morphine Epidural Advanced Consumer Information (Micromedex)
  • Morphine Injection Advanced Consumer Information (Micromedex)
  • Morphine Sulfate AHFS DI Monographs (ASHP)

Thursday, July 21, 2011

Nuvigil


Nuvigil is a brand name of armodafinil, approved by the FDA in the following formulation(s):


NUVIGIL (armodafinil - tablet; oral)



  • Manufacturer: CEPHALON

    Approval date: June 15, 2007

    Strength(s): 150MG, 250MG [RLD], 50MG

Has a generic version of Nuvigil been approved?


No. There is currently no therapeutically equivalent version of Nuvigil available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Nuvigil. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil
    Patent 7,132,570
    Issued: November 7, 2006
    Inventor(s): Neckebrock; Olivier & Leproust; Pierre
    Assignee(s): Cephalon France
    The invention relates to a process for the preparation of crystalline forms of the optical enantiomers of modafinil, comprising stages comprising: i) dissolving one of the optical enantiomers of modafinil in a solvent other than ethanol, ii) crystallising the modafinil enantiomer, iii) recovering the crystalline form of the modafinil enantiomer so obtained. The invention also relates to a process for the preparation of the optical enantiomers of modafinil.
    Patent expiration dates:

    • December 18, 2023
      ✓ 
      Drug substance
      ✓ 
      Drug product


    • June 18, 2024
      ✓ 
      Pediatric exclusivity




  • Pharmaceutical formulations of modafinil
    Patent 7,297,346
    Issued: November 20, 2007
    Inventor(s): Corvari; Vincent & Grandolfi; George & Parikh; Alpa
    Assignee(s): Cephalon Inc.
    The present invention is related to compositions of modafinil, including compositions of modafinil and one or more diluents, disintegrants, binders and lubricants, and the processes for their preparation thereof.
    Patent expiration dates:

    • November 29, 2023
      ✓ 
      Drug product


    • May 29, 2024
      ✓ 
      Pediatric exclusivity




  • Acetamide derivative having defined particle size
    Patent RE37516
    Issued: January 15, 2002
    Inventor(s): Peter E.; Grebow & Vincent; Corvari & David; Stong
    Assignee(s): Cephalon, Inc.
    Pharmaceutical compositions comprising modafinil in the form of particles of defined size. The particle size of modafinil can have a significant effect on the potency and safety profile of the drug.
    Patent expiration dates:

    • October 6, 2014
      ✓ 
      Patent use: IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE SLEEPINESS ASSOCIATED WITH NARCOLEPSY, OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME, AND SHIFT WORK SLEEP DISORDER
      ✓ 
      Drug product


    • April 6, 2015
      ✓ 
      Pediatric exclusivity



See also...

  • Nuvigil Consumer Information (Drugs.com)
  • Nuvigil Consumer Information (Wolters Kluwer)
  • Nuvigil Consumer Information (Cerner Multum)
  • Nuvigil Advanced Consumer Information (Micromedex)
  • Nuvigil AHFS DI Monographs (ASHP)
  • Armodafinil Consumer Information (Wolters Kluwer)
  • Armodafanil Consumer Information (Cerner Multum)
  • Armodafinil Consumer Information (Cerner Multum)
  • Armodafinil Advanced Consumer Information (Micromedex)
  • Armodafinil AHFS DI Monographs (ASHP)

Clofamox




Clofamox may be available in the countries listed below.


Ingredient matches for Clofamox



Amoxicillin

Amoxicillin is reported as an ingredient of Clofamox in the following countries:


  • Argentina

International Drug Name Search

Tuesday, July 19, 2011

Etoposide




In the US, Etoposide (etoposide systemic) is a member of the drug class mitotic inhibitors and is used to treat Cancer, Hodgkin's Lymphoma, Ovarian Cancer, Small Cell Lung Cancer and Testicular Cancer.

US matches:

  • Etoposide

  • Etoposide Capsules

  • Etoposide phosphate

  • Etoposide Oral, Intravenous

  • Etoposide Capsule

UK matches:

  • Etoposide 20 mg/ml Injection (SPC)

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

L01CB01

CAS registry number (Chemical Abstracts Service)

0033419-42-0

Chemical Formula

C29-H32-O13

Molecular Weight

588

Therapeutic Category

Antineoplastic agent

Chemical Name

4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-ß-D-glucopyranoside)

Foreign Names

  • Etoposidum (Latin)
  • Etoposid (German)
  • Etoposide (French)
  • Etoposido (Spanish)

Generic Names

  • Etoposide (OS: JAN, USAN, DCIT, BAN)
  • Étoposide (OS: DCF)
  • EPE (IS)
  • VP 16213 (IS: Bristol-Myers)
  • Etoposid (PH: Ph. Eur. 6)
  • Etoposide (PH: BP 2010, Ph. Int. 4, USP 32, Ph. Eur. 6)
  • Etoposidum (PH: Ph. Int. 4, Ph. Eur. 6)
  • Etoposide Phosphate (OS: USAN)
  • BMY 40481 (IS: Bristol-Myers)

Brand Names

  • Celltop
    Baxter, Belgium; Baxter, France


  • Cryosid
    Cryopharma, Mexico


  • Ebeposid
    Ebewe, Slovenia


  • Eposin
    Emporio, Slovenia; Med, Turkey; Medac, United Arab Emirates; Medac, Bahrain; Medac, Egypt; Medac, United Kingdom; Medac, Iraq; Medac, Iran; Medac, Jordan; Medac, Kuwait; Medac, Lebanon; Medac, Oman; Medac, Qatar; Medac, Saudi Arabia; Medac, Syria; Medac, Yemen; Pharmachemie, Sri Lanka; Pharmachemie, Malaysia; Pharmachemie, Taiwan; Pharmachemie, South Africa; Tedec Meiji, Spain; Teva, Belgium; Teva, Norway; Teva, Sweden


  • Epsidox
    Chile, Chile


  • Etobion
    Medicus, Greece


  • Eto-cell
    Cell pharm, Germany


  • Etocris
    LKM, Argentina


  • Eto-GRY
    Teva-Gry, Germany


  • Etomedac
    Medac, Germany; Medac, Luxembourg


  • Etonco
    Armstrong, Mexico


  • Etonolver
    Nolver, Venezuela


  • Etoposid Ebewe
    Ebewe, Austria; Ebewe, Estonia; Ebewe, Hungary; Ebewe, Indonesia; Ebewe, Israel; Ebewe, Lithuania; Ebewe, Luxembourg; Ebewe, Latvia; Ebewe, Poland; Ebewe, Romania; Ebewe, Serbia; Ebewe, Russian Federation; Ebewe, Tunisia; Ferron, Indonesia; Liba, Turkey; Sandoz, Switzerland


  • Etoposid Hexal
    Hexal, Germany


  • Etoposid Meda
    Meda, Denmark; Meda, Sweden


  • Etoposid Pfizer
    Pfizer, Austria; Pfizer, Georgia


  • Etoposid Sandoz
    Sandoz, Germany


  • Etoposid
    Meda, Norway


  • Etoposide Actavis
    Sindan, Bulgaria


  • Etoposide Aeon
    Aeon, Greece


  • Etoposide APP
    Abraxis, Switzerland


  • Etoposide Crinos
    Crinos, Italy


  • Etoposide DBL
    Hospira, Indonesia; Hospira, Singapore; Mayne, Hong Kong; Tempo Scan Pacific, Indonesia


  • Etoposide Ebewe
    Ebewe, Belgium; Ebewe, Bulgaria; Ebewe, Georgia; Ebewe, Italy; Ebewe, Myanmar; Ebewe, Vietnam; Pharmanel, Greece; Würth, Croatia (Hrvatska)


  • Etoposide Fidia
    Fidia, Italy


  • Etoposide Injection
    Hospira, Australia; Mayne, New Zealand; PfizerPerth, Australia


  • Etoposide Merck
    Merck Génériques, Tunisia


  • Etoposide Mylan
    Mylan, France


  • Etoposide Pfizer
    Pfizer, Switzerland; Pfizer, Denmark; Pfizer, Finland; Pfizer, Philippines; Pfizer, Singapore


  • Etoposide Pharmachemie
    Chemipharm, Greece


  • Etoposide Pharmacia
    Pfizer, Vietnam


  • Etoposide Pierre Fabre
    PF, Luxembourg; Pierre Fabre, Romania


  • Etoposide Teva
    Med, Turkey; Pharmachemie, Bulgaria; Teva, Czech Republic; Teva, Hungary; Teva, Lithuania; Teva, Latvia; Teva, Slovakia; Teva Santé, France; Teva-NL, Italy


  • Etoposide
    Accord, United States; APP, United States; Atafarm, Turkey; Bedford, United States; Genpharm, United States; Hospira, United States; Marsam, United States; Mediline, Israel; Mylan, United States; Pfizer, Croatia (Hrvatska); Pfizer, Serbia; Pharmachemie, United States; SuperGen, United States; Teva, Israel


  • Etoposide-Mayne
    Mayne, Luxembourg


  • Etoposid-Lens
    Verofarm, Georgia


  • Etoposido Biocrom
    Biocrom, Argentina


  • Etoposido Centam
    Centrum, Spain


  • Etoposido Delta Farma
    Delta Farma, Argentina


  • Etoposido Ferrer Farma
    Ferrer, Spain


  • Etoposido Filaxis
    Filaxis, Argentina


  • Etoposido GP Pharm
    GP Pharm, Peru


  • Etoposido Microsules
    Microsules, Argentina


  • Etoposido Pfizer
    Pfizer, Peru


  • Etoposido Rontag
    Rontag, Argentina


  • Etoposido Servycal
    Servycal, Argentina; Servycal, Peru


  • Etoposido Smaller
    Smaller, Spain


  • Etoposido Teva
    Teva, Spain


  • Etoposido Varifarma
    Varifarma, Argentina


  • Etoposido World Pharma
    World Pharma, Peru


  • Etoposido
    Baxter, Chile; Bestpharma, Chile; Kampar, Chile; Pfizer, Chile


  • Etoposid-Teva
    Teva Pharma, Switzerland


  • Etopul
    Korea United Pharm, Georgia; Novell, Indonesia


  • Etosid
    Cemelog-BRS, Bulgaria; Cipla, India; Pharmaceutical, Venezuela


  • Euvaxon
    Teva, Argentina


  • Fytosid
    Biogalenic, Venezuela; Dabur, Georgia; Dabur, Sri Lanka; Dabur, Myanmar; Dabur, Philippines


  • Lastet
    Cancernova, Germany; Euro Nippon Kayaku, Poland; Khandelwal, India; Nippon, Bulgaria; Nippon Kayaku, Bulgaria; Nippon Kayaku, Czech Republic; Nippon Kayaku, Georgia; Nippon Kayaku, Hungary; Nippon Kayaku, Japan; Nippon Kayaku, Latvia; Nippon Kayaku, Oman; Nippon Kayaku, Serbia; Nippon Kayaku, Taiwan; Onko-Koçsel, Turkey; Pfizer, Chile; Refasa, Peru


  • Lastet S
    Nippon Kayaku, Japan


  • Neoplaxol
    Richmond, Argentina; Richmond, Peru


  • Neoposid
    NeoCorp, Germany


  • Oncoposido
    Biotoscana, Colombia


  • P&U Etoposide
    Pfizer, South Africa


  • Percas
    Ivax, Argentina


  • Posyd
    Combiphar, Indonesia; Pharmachemie, Indonesia


  • Riboposid
    Hikma, Germany


  • Sintopozid
    Actavis, Hungary; Sindan, Poland; Sindan, Romania


  • Toposar
    Pfizer, United States


  • Toposide
    Pharmacia & Upjohn, Romania


  • Toposin
    Pharmachemie, Netherlands


  • VepeGal
    Galenika, Serbia


  • Vepesid
    Bristol-Myers Squibb, Argentina; Bristol-Myers Squibb, Austria; Bristol-Myers Squibb, Australia; Bristol-Myers Squibb, Bosnia & Herzegowina; Bristol-Myers Squibb, Belgium; Bristol-Myers Squibb, Brazil; Bristol-Myers Squibb, Switzerland; Bristol-Myers Squibb, Colombia; Bristol-Myers Squibb, Czech Republic; Bristol-Myers Squibb, Czech Republic; Bristol-Myers Squibb, Germany; Bristol-Myers Squibb, Denmark; Bristol-Myers Squibb, Estonia; Bristol-Myers Squibb, Spain; Bristol-Myers Squibb, Finland; Bristol-Myers Squibb, United Kingdom; Bristol-Myers Squibb, Georgia; Bristol-Myers Squibb, Greece; Bristol-Myers Squibb, Hong Kong; Bristol-Myers Squibb, Hungary; Bristol-Myers Squibb, Ireland; Bristol-Myers Squibb, Italy; Bristol-Myers Squibb, Japan; Bristol-Myers Squibb, Lithuania; Bristol-Myers Squibb, Luxembourg; Bristol-Myers Squibb, Mexico; Bristol-Myers Squibb, Netherlands; Bristol-Myers Squibb, Norway; Bristol-Myers Squibb, New Zealand; Bristol-Myers Squibb, Philippines; Bristol-Myers Squibb, Poland; Bristol-Myers Squibb, Portugal; Bristol-Myers Squibb, Romania; Bristol-Myers Squibb, Serbia; Bristol-Myers Squibb, Russian Federation; Bristol-Myers Squibb, Sweden; Bristol-Myers Squibb, Slovenia; Bristol-Myers Squibb, Slovakia; Bristol-Myers Squibb, Thailand; Bristol-Myers Squibb, Turkey; Bristol-Myers Squibb, Taiwan; Bristol-Myers Squibb, United States; Bristol-Myers Squibb, South Africa; Er-Kim, Turkey; Medcor, Netherlands; PharmaSwiss, Croatia (Hrvatska)


  • Vépéside
    Novartis, Tunisia


  • VP-16
    Bristol-Myers Squibb, Chile


  • VP-Gen
    Bioprofarma, Argentina


  • Etopofos
    Bristol-Myers Squibb, Austria; Bristol-Myers Squibb, Denmark; Bristol-Myers Squibb, Finland; Bristol-Myers Squibb, Norway; Bristol-Myers Squibb, Sweden


  • Etopophos
    Bristol-Myers Squibb, United Arab Emirates; Bristol-Myers Squibb, Australia; Bristol-Myers Squibb, Bahrain; Bristol-Myers Squibb, Switzerland; Bristol-Myers Squibb, Cote D'ivoire; Bristol-Myers Squibb, Germany; Bristol-Myers Squibb, Egypt; Bristol-Myers Squibb, France; Bristol-Myers Squibb, Gabon; Bristol-Myers Squibb, United Kingdom; Bristol-Myers Squibb, Guinea; Bristol-Myers Squibb, Iraq; Bristol-Myers Squibb, Iran; Bristol-Myers Squibb, Jordan; Bristol-Myers Squibb, Kuwait; Bristol-Myers Squibb, Lebanon; Bristol-Myers Squibb, Luxembourg; Bristol-Myers Squibb, Mali; Bristol-Myers Squibb, Niger; Bristol-Myers Squibb, New Zealand; Bristol-Myers Squibb, Oman; Bristol-Myers Squibb, Qatar; Bristol-Myers Squibb, Saudi Arabia; Bristol-Myers Squibb, Senegal; Bristol-Myers Squibb, Syria; Bristol-Myers Squibb, Chad; Bristol-Myers Squibb, Togo; Bristol-Myers Squibb, United States; Bristol-Myers Squibb, Yemen; Bristol-Myers Squibb, South Africa


  • Nexvep
    Bristol-Myers Squibb, Brazil


  • Vépéside
    Genopharm, France

International Drug Name Search

Glossary

BANBritish Approved Name
DCFDénomination Commune Française
DCITDenominazione Comune Italiana
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
PHPharmacopoeia Name
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
SPC Summary of Product Characteristics (UK)
USANUnited States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Sunday, July 17, 2011

Glycoran




Glycoran may be available in the countries listed below.


Ingredient matches for Glycoran



Metformin

Metformin hydrochloride (a derivative of Metformin) is reported as an ingredient of Glycoran in the following countries:


  • Japan

International Drug Name Search

Wednesday, July 13, 2011

Ultram


See also: Generic Ultram ER


Ultram is a brand name of tramadol, approved by the FDA in the following formulation(s):


ULTRAM (tramadol hydrochloride - tablet; oral)



  • Manufacturer: JANSSEN PHARMS

    Approval date: March 3, 1995

    Strength(s): 50MG [RLD][AB]

Has a generic version of Ultram been approved?


A generic version of Ultram has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Ultram and have been approved by the FDA:


tramadol hydrochloride tablet; oral



  • Manufacturer: ALPHAPHARM

    Approval date: November 21, 2002

    Strength(s): 50MG [AB]


  • Manufacturer: ALVOGEN

    Approval date: November 28, 2011

    Strength(s): 50MG [AB]


  • Manufacturer: AMNEAL PHARMS

    Approval date: June 20, 2002

    Strength(s): 50MG [AB]


  • Manufacturer: APOTEX

    Approval date: July 10, 2002

    Strength(s): 50MG [AB]


  • Manufacturer: CARACO

    Approval date: June 19, 2002

    Strength(s): 50MG [AB]


  • Manufacturer: MALLINCKRODT

    Approval date: June 25, 2002

    Strength(s): 50MG [AB]


  • Manufacturer: MUTUAL PHARM

    Approval date: June 20, 2002

    Strength(s): 50MG [AB]


  • Manufacturer: MYLAN

    Approval date: June 21, 2002

    Strength(s): 50MG [AB]


  • Manufacturer: NORTHSTAR HLTHCARE

    Approval date: May 26, 2010

    Strength(s): 50MG [AB]


  • Manufacturer: PLIVA

    Approval date: July 1, 2002

    Strength(s): 50MG [AB]


  • Manufacturer: SANDOZ

    Approval date: June 25, 2002

    Strength(s): 50MG [AB]


  • Manufacturer: TEVA

    Approval date: June 19, 2002

    Strength(s): 50MG [AB]


  • Manufacturer: WATSON LABS

    Approval date: June 24, 2002

    Strength(s): 50MG [AB]


  • Manufacturer: ZYDUS PHARMS USA INC

    Approval date: January 31, 2011

    Strength(s): 50MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ultram. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Analgesic regimen
    Patent 6,339,105
    Issued: January 15, 2002
    Inventor(s): Marc; Kamin & William; Olson
    Assignee(s): Ortho-McNeil Pharmaceutical, Inc.
    A regimen for the administration of tramadol for the treatment of analgesia is described. The regimen involves a slower initial titration rate of tramadol which results in a significantly lower percentage of discontinuations of therapy due to a lower incidence and severity of side effects.
    Patent expiration dates:

    • October 12, 2019
      ✓ 
      Patent use: A TITRATION DOSING REGIMEN FOR THE TREATMENT OF PAIN USING AN INITIAL DOSE OF ABOUT 25MG


    • April 12, 2020
      ✓ 
      Patent use: A TITRATION DOSING REGIMEN FOR THE TREATMENT OF PAIN USING AN INITIAL DOSE OF ABOUT 25MG
      ✓ 
      Pediatric exclusivity



See also...

  • Ultram Consumer Information (Drugs.com)
  • Ultram Consumer Information (Wolters Kluwer)
  • Ultram Consumer Information (Cerner Multum)
  • Ultram Advanced Consumer Information (Micromedex)
  • Ultram AHFS DI Monographs (ASHP)
  • Tramadol Consumer Information (Drugs.com)
  • Tramadol Consumer Information (Wolters Kluwer)
  • Tramadol Extended-Release Capsules Consumer Information (Wolters Kluwer)
  • Tramadol Extended-Release Tablets Consumer Information (Wolters Kluwer)
  • Tramadol Orally Disintegrating Tablets Consumer Information (Wolters Kluwer)
  • Tramadol Consumer Information (Cerner Multum)
  • FusePaq Synapryn Advanced Consumer Information (Micromedex)
  • Tramadol Advanced Consumer Information (Micromedex)
  • Tramadol Hydrochloride AHFS DI Monographs (ASHP)

Dideral




Dideral may be available in the countries listed below.


Ingredient matches for Dideral



Propranolol

Propranolol hydrochloride (a derivative of Propranolol) is reported as an ingredient of Dideral in the following countries:


  • Turkey

International Drug Name Search

Monday, July 11, 2011

Amipar




Amipar may be available in the countries listed below.


Ingredient matches for Amipar



Paracetamol

Paracetamol is reported as an ingredient of Amipar in the following countries:


  • Poland

International Drug Name Search

Sertrabian




Sertrabian may be available in the countries listed below.


Ingredient matches for Sertrabian



Sertraline

Sertraline hydrochloride (a derivative of Sertraline) is reported as an ingredient of Sertrabian in the following countries:


  • Spain

International Drug Name Search

Friday, July 8, 2011

Cobametacin




Cobametacin may be available in the countries listed below.


Ingredient matches for Cobametacin



Acemetacin

Acemetacin is reported as an ingredient of Cobametacin in the following countries:


  • Japan

International Drug Name Search

Epinefrina GP Pharm




Epinefrina GP Pharm may be available in the countries listed below.


Ingredient matches for Epinefrina GP Pharm



Epinephrine

Epinephrine is reported as an ingredient of Epinefrina GP Pharm in the following countries:


  • Peru

International Drug Name Search

Isosorbidmononitrat 1A Pharma




Isosorbidmononitrat 1A Pharma may be available in the countries listed below.


Ingredient matches for Isosorbidmononitrat 1A Pharma



Isosorbide Mononitrate

Isosorbide Mononitrate is reported as an ingredient of Isosorbidmononitrat 1A Pharma in the following countries:


  • Austria

International Drug Name Search

Wednesday, July 6, 2011

Diclofenac Helvepharm




Diclofenac Helvepharm may be available in the countries listed below.


Ingredient matches for Diclofenac Helvepharm



Diclofenac

Diclofenac sodium salt (a derivative of Diclofenac) is reported as an ingredient of Diclofenac Helvepharm in the following countries:


  • Switzerland

International Drug Name Search

Tuesday, July 5, 2011

Pentoxol




Pentoxol may be available in the countries listed below.


Ingredient matches for Pentoxol



Paclitaxel

Paclitaxel is reported as an ingredient of Pentoxol in the following countries:


  • Chile

International Drug Name Search

Sunday, July 3, 2011

Sibélium




Sibélium may be available in the countries listed below.


Ingredient matches for Sibélium



Flunarizine

Flunarizine dihydrochloride (a derivative of Flunarizine) is reported as an ingredient of Sibélium in the following countries:


  • France

International Drug Name Search

Saturday, July 2, 2011

Silicosel




Silicosel may be available in the countries listed below.


In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Silicosel



Dimeticone

Dimeticone is reported as an ingredient of Silicosel in the following countries:


  • Germany

International Drug Name Search